tbuckley/cabot-search huggingface dataset:
Tc-99m MDP Three-Phase Bone Scintigraphy in Disciplinary Exercise-induced Rhabdomyolysis
Authors: SEOK T. LIM, MYUNG-HEE SOHN, SOON-A PARK
Journal: Clinical Nuclear Medicine (2000)

Tc-99m MDP bone scintigraphy is useful in clinically suspected rhabdomyolysis as a diagnostic test and as a test to localize and quantify muscular involvement. A 14-year-old boy had myalgia and painful swelling of both thighs after strenuous disciplinary exercise in middle school. He underwent three-phase bone scintigraphy (TPBS) with Tc-99m MDP to identify the origin of his chief symptoms. In the acute stage of rhabdomyolysis, TPBS showed increased perfusion and blood pooling and increased symmetric skeletal MDP uptake in both thighs. Interestingly, the skeletal MDP uptake was more prominent in the abductor muscles than in the adductor muscles. In the recovery stage, the TPBS revealed marked improvement of skeletal MDP uptake, more than improvement of perfusion and blood pooling in both thighs.
Abstract 921: HER3 reactivation: A compensatory shift between Akt-mediated positive and negative feedback loops in HER2-overexpressed human breast cancer cells
Authors: Patrick Ming Kuen Tang, Fenix Leung, Merel Gijsen, Adrian L. Harris, Anthony Kong
Journal: Cancer Research (2011)

Abstract The activated serine/threonine protein kinase Akt (or Protein Kinase B, PKB) regulates cell survival and metabolism by phosphorylation of numerous adaptor proteins and kinases. Akt is known as a key downstream target of HER3 signaling axis. It is also suggested to be an important modulator for the HER3 reactivation via a compensatory shift in the HER3 phosphorylation-dephosphorylation equilibrium during TKI-induced drug resistance. However, the mechanism of Akt-mediated HER3 reactivation during TKI treatment is still unclear. Interestingly, HER3 was rapidly dephosphorylated when an Akt inhibitor (Akt inhibitor VIII, Akti) was applied to mimic the inhibitory effect of TKI on the PI3K/Akt axis. The same phenomenon was also found when PI3K inhibitor was utilized instead. This positive feedback within the HER3 signaling axis was shown to be mediated by PTPN9, a phosphatase that is known to negatively regulate the EGFR activation state. We showed that PTPN9 was upregulated once Akt was inhibited. This lead to EGFR deactivation and eventually caused the dephosphorylation of HER3, which was reversed when PTPN9 was locked down. Furthermore, reactivation of HER3 was also found in the Akti-treated cells at 24h. This was shown to be due to a negative feedback loop via the ADAM17-mediated heregulin release, which could be suppressed by ADAM17 inhibitor INCB4298. Our results are crucial in advancing our knowledge in HER3/PI3K/Akt axis, where the positive loop revealed the mechanism of Akt suppression in regulating HER3 phosphorylation; and the negative loop is implicated in resistance mechanisms to various targeted therapies that affect Akt activity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 921. doi:10.1158/1538-7445.AM2011-921
Abstract P4-03-05: The Warburg Effect and RUNX2-Regulated Metabolic Switching in Breast Cancer: A New Therapeutic Target?
Authors: T Passaniti, S Chumsri, G Girnun, A Brodie, M. Choe
Journal: Cancer Research (2010)

Abstract Breast cancer (BC) is the leading cause of cancer deaths among women in North America and Western Europe. Numerous studies have shown that breast tumor progression is associated with a switch from mitochondrial oxidative phosphorylation (OxPhos) to increased utilization of glucose and aerobic glycolysis (Warburg effect). Uncovering underlying mechanisms regulating this progression may lead to innovative approaches for treatment. The RUNX2 DNA-binding transcription factor is expressed in highly aggressive BC and regulates bone metastasis in animal models. We observed increased expression of RUNX2 in primary human ductal carcinoma in situ (DCIS), which correlated with grade and proliferative index (Ki67 staining), decreased estrogen receptor/progesterone receptor expression (ER/PR status), increased glucose uptake values by PET scanning, and increased expression of the glucose transporter, GLUT1. Further, more than 80% (9 out of 11) of triple-negative BC cell lines examined expressed RUNX2. Therefore, to test the hypothesis that RUNX2 may alter the metabolic status of breast cancers and increase their dependence on glycolysis during tumor progression, we have generated a Tet-OFF model system using MCF7 cells with inducible RUNX2 expression. RUNX2-positive MCF7 cells exhibited increased cell death under conditions of glucose depletion or when treated with 2-deoxy-glucose, a competitive inhibitor of hexokinase II. Conversely, RUNX2-positive cells were more resistant to OxPhos inhibitors (rotenone, oligomycin) than RUNX2-negative cells. We also observed higher expression levels of GLUT1 and pAKT in RUNX2-positive MCF7 cells. Hypoxia-inducible factor-α (HIF1α) is a transcription factor that regulates cancer metabolism through its activation of glycolytic genes, while SIRT6, an NAD-dependent deacetylase, is a negative regulator of HIF1α activity. This occurs, in part, via inhibition of HIF1α transcriptional activity. RUNX2-positive or negative cells expressed HIF1α in response to glucose but RUNX2-positive cells exhibited lower SIRT6 expression than RUNX2-negative cells, suggesting that with the loss of SIRT6, HIF1α might be more active in promoting glycolysis in the presence of RUNX2. These results suggest that RUNX2 may have clinical diagnostic value as an indicator of BC metabolic stress and predictor of poor prognosis. Current strategies are utilizing computer-assisted drug design to develop RUNX-specific inhibitors to target BC glycolysis and tumor growth. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-03-05.
Radionuclide Imaging of Cardiac Hydatid Cyst
Authors: GÜN KARA, GÜLSEREN ARAS, ÖZLEM N. KÜÇÜK
Journal: Clinical Nuclear Medicine (2003)

From Ankara University, School of Medicine, Department of Nuclear Medicine, Ankara, Turkey Received for publication June 19, 2002. Revision accepted September 19, 2002. Correspondence: Gün Kara, Ankara Üniversitesi, Tip Fakültesi Cebeci Hastanesi, Nükleer Tip Merkezi Cebeci, Ankara, Turkey. E-mail: [email protected]
Abstract 1700: The prognostic marker <i>SHP-1</i> promoter <i>2</i> hypermethylation can detect lymph node micrometastases in early stage NSCLC
Authors: Chanida Vinayanuwattikun, Poonchavist Chantranuwatana, Apiwat Mutirangura, Virote Sriuranpong
Journal: Cancer Research (2012)

Abstract Introduction; Despite adequate surgical management of stage I non-small cell lung cancer, many patients still relapse and die of their disease. Micrometastases within lymph nodes might not be detected by standard H&amp;E method. The authors conducted the study of epithelial methylation marker, SHP-1 Promoter 2 (SHP1P2) methylation as a potential molecular marker to determine its association with a high risk of disease relapse in stage I resectable non-small cell lung cancer (NSCLC). Method; Lymph nodes from resectable NSCLC stage II-IIIA were examined as a test set. All study participants had stage I NSCLC and underwent curative resection during 2001-2007 and had follow-up at The King Chulalongkorn Memorial Hospital, Bangkok, Thailand. No adjuvant treatment was given. Recurrence of disease within 40 months after resection was defined as high risk. Results: In stage II-IIIA, 75 lymph nodes were analyzed. SHP1P2 methylation was significantly higher in lymph nodes containing H&amp;E detectable metastasis compared with histologically negative nodes (p=0.008). One hundred and ninety-eight lymph nodes from 23 patients with stage I non-small cell lung cancer were analyzed in this study. Seven patients (30%) relapsed within 40 months. Median follow-up period from surgery to relapsed of disease or censored if no relapse of disease was 56 months (range 6-109 months). All clinical/pathologic features were similar except for a larger primary tumor size in the early relapse group. Median tumor size is 5 cms (range 2-11.5) vs 2.5 cms (range 1.5-5.7) in high and low risk group respectively. Multivariate logistic-regression analyses included demographic data (sex, age, staging, tumor grading, size, type of surgery and number of resected lymph node) and SHP1P2 methylation status were done. A high absolute level of SHP1P2 methylation (&amp;gt;58%) in analyzed resected lymph node was associated with early relapse, sensitivity 71% and specificity 99% (HR 0.43-1.04; p=0.07 (univariate); p=.002 (multivariate) with an odds ratio of recurrent cancer of 32). Conclusion: SHP1P2 methylation of resected lymph node of stage I NSCLC treated with curative intent of surgery is associated with early relapsed of disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1700. doi:1538-7445.AM2012-1700
LONG-TERM OUTCOMES OF PATIENTS TREATED WITH EVEROLIMUS-ELUTING BIORESORBABLE VASCULAR SCAFFOLDS VERSUS EVEROLIMUS-ELUTING METALLIC STENTS: A PROPENSITY SCORE COMPARISON OF PATIENTS ENROLLED IN THE ABSORB EXTEND AND SPIRIT TRIALS
Authors: Jose de Ribamar Costa, Alexandre Abizaid
Journal: Journal of the American College of Cardiology (2016)
FRI0298 The prevalence of metabolic syndrome in a mexican pediatric population with systemic lupus erythematosus and its association with lupus activity.
Authors: T. A. Gomez-Marcial, J. Sepulveda, E. Solis-Vallejo, O. Vera-Lastra
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Introduction: The metabolic syndrome (MS) is a cluster of the most dangerous risk factors for cardiovascular disease and type 2 diabetes, which include abdominal obesity, high cholesterol, high blood pressure, diabetes or raised fasting plasma glucose. Metabolic syndrome is a risk factor that increases cardiovascular morbidity and mortality in adults and increased morbidity in children and adolescents. The prevalence of metabolic syndrome in healthy Mexican adolescents it had been reported up to 13% according International Diabetes Federation (IDF). <h3>Objectives</h3> Objective: To investigate the prevalence of metabolic syndrome in a pediatric population with SLE and its association with lupus activity versus healthy controls. <h3>Methods</h3> Patients and methods: we studied 37 children (women 32 and men 5) with SLE and 100 healthy children (women 48 and men 52) with age between 10 to 16 years old and complete clinical charts. Exclusion criteria: primary antiphospholipid syndrome, overlap syndrome of connective tissue disease, patients in treatment with drugs to decrease lipids and glucose. The following were determined: total cholesterol (TC), high density cholesterol (HDLc), triglycerides, glucose, antinuclear antibodies, blood cell count and somatometry. For the diagnosis of MS we applied the criteria of the IDF and for the SLE activity we used Mex-SLEDAI. <h3>Results</h3> Results: There were 37 children with age of 12.2±1.9 year and control 12.1 ± 1.5 year. The mean evolution time of SLE was 2.8±2.5 years. MS was found in 11 of 37 (32%) versus control 11 of 100 (10.78%), p = 0.0021. When we analyzed the components of the MS we find statistical differences in triglyceride levels 151 mg/dl [71-504 mg/dl] vs 91 mg/dl [32-504 mg/dl] (p= 0.0001), arterial hypertension according to age and gender percentile (&gt;95) we found 19 of 37 (37.14%) in SLE patients vs 16 of 100 ( 15.6%) healthy control, (p=0.0037) and glucose levels 79.05 mg/dl + 10.82mg/dl vs 83.7 mg/dl + 7.31 mg/dl (<i>p</i>=0.0001) respectively. We did not find statistical significance between SLE activity and metabolic syndrome with active SLE 31.03% versus 37.5% cases with non active SLE (<i>p</i>= 0.47) <h3>Conclusions</h3> Conclusion: The prevalence of MS in Mexican pediatric patients with SLE was 32% in comparison with healthy children in 11%. The MS was not associated with SLE activity. It is important to identify children with SLE and MS, implementing therapeutic strategies for the prevention of diabetes or cardiovascular disease in the future. <b>Disclosure of Interest</b>: None Declared
P6 Temporal relationships between lung cancer MDT recommendations and final outcomes
Authors: K Shah, L Fairclough, R Sundar, SCO Taggart
Journal: Thorax (2013)

<h3>Introduction and Objective</h3> A previous study [1] has identified a discordancy rate of 33% between MDT treatment decision and actual treatment given to patients not suitable for best supportive care. The Northwest Sector Lung Cancer MDT (SMDT) provides recommendations for treatment for approximately 700 new diagnoses/year attending the Salford, Wigan and Bolton catchment area. The Salford Service is centralised around the Lead Clinician who assesses and refers &gt;90% of patients to SMDT (c.f. &lt;50% Wigan &amp; Bolton). A detailed proforma is completed for each patient detailing performance score, co-morbidity and all diagnostic data. This study sets out to determine the temporal rates of discordance between SMDT recommendations and actual treatment pursued for Salford and Wigan. <h3>Method</h3> Using a 1:2 random selection of all patients from Salford &amp; Wigan diagnosed in 2011 and 2012, the hospital notes were examined to identify the SMDT recommendation and subsequent treatment received by the patient. Patients referred for Best Supportive Care were excluded. Any discordance was further explored by review of the notes. <h3>Results</h3> The study identified a total of 441 patients; 213 (Salford) and 228 (Wigan). The discordance rates for Salford were 8% (2011), 12.8% (2012) &amp; 10.4% (combined) c.f. 26.9% (2011), 36.9% (2012) and 32.4% for Wigan. The overall SMDT discordancy rate was 17.7% (2011), 27.0% (2012) &amp; 19.9% (combined). Discordance occurred most commonly due to co-morbidity health concerns (44.6%), patient wishes (15.7%) and as a result of new clinical information becoming available (27.7%). <h3>Conclusions</h3> SMDT recommendations are dependent on a detailed knowledge of patient wishes, co-morbidity and stage of disease. Discordance reflects weaknesses in patient assessment prior to referral to SMDT. Centralisation of assessment before referral to SMDT is associated with improved and acceptable discordancy rates. We recommend assessment by a dedicated Lung Cancer Clinician ahead of referral to SMDT. <h3>Reference</h3> Pemberton L <i>et al.</i> Do treatment decisions made at lung cancer multi-disciplinary team meetings (MDTs) reflect the actual treatment given in practice? Lung Cancer, Volume 79, Supplement 1, January 2013, Page S36.
FDG PET/CT in Follicular Dendritic Cell Sarcoma with Extensive Peritoneal Involvement
Authors: Aisheng Dong, Yang Wang, Changjing Zuo
Journal: Clinical Nuclear Medicine (2013)

Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm that originates from follicular dendritic cells. A 33-year-old woman was referred because of a 2-month history of lower abdominal fullness. Enhanced T1-weighted MR images showed enhancement of the thickened pelvic peritoneum. FDG PET/CT was performed showing multiple FDG-avid lymph nodes in the parapharyngeal, bilateral supraclavicular, left axillary, mediastinal, and abdominal regions, and intense FDG uptake in the thickened mesentery and peritoneum. Pathologic findings of both the left supraclavicular lymph node and peritoneal biopsy specimens were consistent with high-grade FDCS. In this case, extensive peritoneal involvement by FDCS was unusual.
Creative Commons and the Openness of Open Access
Authors: Michael W. Carroll
Journal: New England Journal of Medicine (2013)

Interview with Dr. Martin Frank and Prof. Michael Carroll on traditional and open-access scientific publishing. (23:50)Download As part of the open-access movement and with the mission of expanding the terms of use for increasingly accessible information, Creative Commons has produced six copyright licenses that permit a range of uses beyond fair use, subject to certain conditions.
CATHETER-BASED TREATMENT VERSUS SYSTEMIC THROMBOLYSIS IN ACUTE MASSIVE PULMONARY EMBOLISM: A COMPREHENSIVE META-ANALYSES
Authors: Navkaranbir S. Bajaj, Rajat Kalra, Pankaj Arora, Sameer Ather, Jason Guichard, William Lancaster, David C. McGiffin, Mustafa Ahmed
Journal: Journal of the American College of Cardiology (2016)
The Prevalence of Bone Aluminum Deposition in Renal Osteodystrophy and Its Relation to the Response to Calcitriol Therapy
Authors: Susan M. Ott, Norma A. Maloney, Jack W. Coburn, Allen C. Alfrey, Donald J. Sherrard
Journal: New England Journal of Medicine (1982)

A histochemical stain for bone aluminum allowed us to determine the prevalence and staining characteristics of aluminum in renal osteodystrophy. The staining method correlated well with the results of atomic-absorption studies in 96 samples (r = 0.81; P less than 0.001). We examined 315 bone-biopsy samples. No aluminum was seen in controls or patients with nonrenal bone disease. In renal osteodystrophy, the mean level of stainable aluminum was significantly higher in osteomalacic lesions (1.12 +/- 0.09 mm per square millimeter of tissue area) than in mild, mixed, of fibrotic lesions (0.43 +/- 0.06, 0.34 +/- 0.11, and 0.10 +/- 0.03 mm per square millimeter, respectively; P less than 0.001). Seventy per cent of osteomalacic samples had heavy aluminum staining. The bone-apposition rate, measured by double tetracycline labels, was low in 89 per cent of the samples with high levels of aluminum. The mean level of stainable bone aluminum in patients who had a clinical response to calcitriol was significantly lower than in those who did not respond (0.13 +/- 0.4 vs. 1.06 +/- 0.9 mm per square millimeter; P less than 0.01). We conclude that aluminum deposition is associated with impaired bone formation or mineralization and with a poor response to calcitriol therapy.
Quantitative Evaluation of Incomplete Embolization in a Patient With Portosystemic Shunt by Per-rectal Portal Scintigraphy
Authors: Ari Chong, Jung-Min Ha, Jong-Ryool Oh, Jung-Joon Min, Hee-Seung Bom, Ho-Chun Song
Journal: Clinical Nuclear Medicine (2011)

Per-rectal portal scintigraphy is an easy and noninvasive method for assessing the status of a portosystemic shunt. This approach is typically used for determining shunt index in cirrhotic patients with portal hypertension. We report a case where per-rectal portal scintigraphy proved useful for quantitative evaluation of portosystemic shunt after incomplete embolization.
THU0171 Which Adverse Events (AES) of Biological Therapy (BT) Led to Discontinuation of Treatment in A Cohort of 377 JIA Patients in Comparison to 1115 Patients Affected by Ra, As, PSA in the Department of Rheumatology of G. Pini Institute
Authors: I. Pontikaki, E.G. Favalli, M. Biggioggero, F. Rovelli, A. Becciolini, M. Gattinara, P.L. Meroni, V. Gerloni
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To report adverse events (AEs), which led to discontinuation of biologics agents, in a large cohort of patients with Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA). <h3>Methods</h3> All patients, non responder or intolerant to DMARDs, treated with Biological Therapy (BT) at the Rheumatologic Centre of the G. Pini Institute (Milan, Italy) from 1999 to 2013 were taken into consideration. <h3>Results</h3> 377 pts affected by JIA, 690 pts affected by RA, 221 pts affected by AS and 204 pts affected by PsA were enrolled in fourtheen years. A total of 220 (58.4%) JIA pts, 388 (56.2%) RA pts, 79 (35.7%) AS pts and 87 (42.6%) PsA pts failed to respond to or did not tolerate the BT. Infusion/injection reactions led to discontinuation in 47 (21.3%) JIA pts, 46 (11.8%) RA pts, 13 (16.4%) SA pts and 8 (9.1%) PsA pts. Cutaneous Diseases occurred in 15 (6.8%) JIA pts, 23 (5.9%) RA pts, 1 (1.2%) AS pt and 3 (3.4%) PsA pts. The adult population, unlike JIA population, frequently discontinued BT for infections and malignancy (infections: 27 (6.9%) RA pts, 7 (8.8%) AS pts and 6 (6.8%) PsA pts; Malignancy: 13 (3.3%) RA pts, 2 (2.5%) AS pts and 3 (3.4%) PsA). In JIA pts the most frequent AEs were: important behavioural alterations (depression, anxiety, aggressiveness), new onset of inflammatory bowel disease, in 10 (4.5%) JIA pts and new onset or flare-up of chronic iridocyclitis (in 17 (7.7%) JIA pts). <h3>Conclusions</h3> In our 14-year experience, BT were well tolerated and safe; most of AEs reported were reversible by discontinuation of therapy. In the adult population the most significant causes of discontinuation were infections and malignancy, while in JIA pts were" important" behavioural alterations, new onset of inflammatory bowel disease and new onset or flare-up of chronic iridocyclitis. The percentage of failure to response was the greatest similarity between the two populations. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5738
Abstract 125: Hematological cancer incidence among semiconductor workers.
Authors: Kyoungho Lee, Joohee Han, Kwansick Kim, Soo-Geun Kim
Journal: Cancer Research (2013)

Abstract Background/objective. There has recently been such great interest in cancer incidence among the semiconductor workers. Therefore, an epidemiological study was conducted to figure out the cancer incidence rate among semiconductor workers and potential factors affecting cancer. Methods. The study was performed for the semiconductor workers employed from 1999 to 2008, and the total number of workers in a cohort was 56,283 who employed for over one month. Cancer incidence rate was analyzed by departments, divisions, job titles, gender, age, viral hepatitis and working duration. We compared the incidence of hematological cancer in this cohort with that expected on the basis of cancer incidence in the general population. Results. Overall, the standardized incidence rate (SIR) for workers indicates 0.76 (95% CI: 0.66-0.86) compared to general population data. In particular, the rate for leukemia was 0.86(0.50-1.47) in the total. Non-Hodgkin's lymphoma was observed high SIR which was not statistically significant among female assembly workers(2.42, 95% CI: 0.78-7.49), whereas in office workers were significant high (5.23, 95% CI: 1.31-20.92). We also found that the hepatitis virus affected in female workers (7.69, 95% CI: 1.08-54.60). Conclusions. We concluded that the SIR for non-Hodgkin's lymphoma among female workers is high because of personal factors and additional research works are considered for some confounder factors. Epidemiological study based on a constant, long-term prospective cohort is required for the future studies. Citation Format: Kyoungho Lee, Joohee Han, Kwansick Kim, Soo-Geun Kim. Hematological cancer incidence among semiconductor workers. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 125. doi:10.1158/1538-7445.AM2013-125